[Edaily Reporter Kim Seung-kwon ] #3billion Inc. has raised expectations for a return to profitability with first-half earnings up approximately 60% year-over-year.

3billion Inc., an AI-based rare disease diagnostics company, announced on the 13th that its consolidated revenue for the first half of 2026 reached 7.2 billion won, a 56% increase from the approximately 4.6 billion won recorded in the same period last year. Second-quarter revenue totaled 3.8 billion won, up 46% year-over-year and 13% from the previous quarter.

Overseas revenue for the first half of the year totaled approximately 4.9 billion won, a 59% increase from the same period last year, accounting for about 69% of total revenue. In particular, amid sustained demand for rare disease diagnostics based on Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), the family-based genetic test “Family Insight,” launched last February, is also generating revenue, primarily from overseas markets.

Domestic revenue also grew by approximately 50% compared to the same period last year, and the profit and loss structure improved. The operating loss for the first half of the year was 3.3 billion won, a 7% decrease from the same period last year, and the operating loss ratio relative to revenue fell by 31 percentage points from 78% to 47%. With revenue growing by 56%, the increase in operating expenses was limited to 29%, reducing the burden of losses.

Consolidated net income for the first half of the year was 5.3 billion won. The company stated, “This is an accounting result reflecting non-cash valuation gains due to changes in the fair value of convertible bonds (CBs) and convertible preferred shares (CPSs) issued last May,” adding, “It is unrelated to actual cash inflows or a return to operating profitability in our core business.”

Building on this momentum, 3billion Inc. is expanding its foundation for mid- to long-term growth. This year, the company raised a total of 30 billion won by issuing 12.5 billion won in convertible bonds (CB) and 17.5 billion won in convertible preferred shares (CPS), which will be used to expand its global diagnostics business and fund R&D for AI-driven new drug development.

The company is also expanding into new diagnostic business areas. Last June, it launched “3B-NEO,” a genome-based newborn screening test (gNBS) for healthy newborns, in overseas markets and was selected as the implementing agency for a newborn screening program led by the Philippine government. Related results are expected to be reflected sequentially starting in the second half of the year.

Kim Chang-won, CEO of 3billion Inc., stated, “In the first half of the year, we continued to achieve revenue growth and improve our profit structure, driven by expanding demand for genetic diagnostics both domestically and internationally.” He added, “We will continue to enhance our competitiveness in the global genomic diagnostics market by expanding our business scope beyond rare disease diagnostics to include prevention-focused services such as newborn screening and family-based genetic testing.”